The amikacin research program: a stepwise approach to validate dosing regimens in neonates
Anne Smits1,2, Aida Kulo3, John van den Anker4,5,6,7
1a Neonatal Intensive Care Unit , VU Medical Center , Amsterdam , The Netherlands.
Expert Opinion on Drug Metabolism & Toxicology
|September 15, 2016
Summary
Optimizing amikacin dosing in neonates requires understanding pharmacokinetics (PK). A validated pharmacometric model considers weight, age, and other factors for safe and effective antibacterial treatment.
Area of Science:
- Neonatal pharmacology
- Pharmacometrics
- Antibacterial drug development
Background:
- Neonatal antibacterial therapy requires precise pharmacokinetic (PK) data for safety and efficacy.
- Amikacin dosing in neonates is complex due to physiological immaturity and variable clinical factors.
- A robust approach is needed to optimize amikacin exposure and minimize toxicity risks.
Purpose of the Study:
- To describe a two-decade approach to developing and validating an amikacin dosing regimen for neonates.
- To incorporate key covariates into a pharmacometric model for improved amikacin exposure.
- To summarize existing literature on amikacin's developmental toxicology in neonates.
Main Methods:
- Utilized pharmacometrics and clinical data, including therapeutic drug monitoring (TDM), for model development.
- Validated the dosing regimen through prospective studies.
- Collected data on deep compartment pharmacokinetics and summarized developmental toxicology literature.
Main Results:
- Developed and validated a pharmacometric dosing regimen for amikacin in neonates.
- The model incorporates covariates such as weight, postnatal age, perinatal asphyxia, and ibuprofen use.
- Established a semi-physiological function for glomerular filtration within the amikacin model.
Conclusions:
- The developed amikacin model provides a foundation for optimizing aminoglycoside dosing and validating PBPK models.
- Further research should investigate safety with additional covariates, biomarkers, and long-term outcomes.
- Implementation initiatives are crucial for disseminating knowledge and improving clinical practice in neonatal antibacterial therapy.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
01:29Drug Dosing: Infants and Children
677
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
677
01:20Estimation of k and VD of Aminoglycosides
293
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
293
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
307
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
307
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
419
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
246
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
246